• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression holistic Treatment for depression

Traditional treatment and medications don't work for a majority of people who are depressed. Personalized treatment may be the solution.

Cue is an intervention platform for digital devices that translates passively acquired normal smartphone sensor data into personalized micro-interventions to improve mental health. We analyzed the best-fitting personalized ML models for each individual using Shapley values to discover their features and predictors. This revealed distinct features that deterministically changed mood over time.

Predictors of Mood

Depression is one of the world's leading causes of mental illness.1 However, only half of those suffering from the disorder receive treatment1. To improve outcomes, clinicians must be able identify and treat patients most likely to benefit from certain treatments.

A customized depression treatment is one method to achieve this. By using sensors for mobile phones, an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from the treatments they receive. Two grants were awarded that total over $10 million, they will use these techniques to determine biological and behavioral predictors of response to antidepressant medications and psychotherapy.

The majority of research done to the present has been focused on sociodemographic and clinical characteristics. These include demographic variables like age, sex and education, clinical characteristics including symptom severity and comorbidities, and biological indicators such as neuroimaging and genetic variation.

A few studies have utilized longitudinal data in order to predict mood in individuals. Many studies do not take into account the fact that moods can be very different between individuals. Therefore, it is crucial to develop methods which permit the analysis and measurement of personal differences between mood predictors and treatment effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to identify patterns of behavior and emotions that are unique to each person.

In addition to these methods, the team developed a machine-learning algorithm to model the changing predictors of each person's depressed mood. The algorithm combines these individual characteristics into a distinctive "digital phenotype" for each participant.

This digital phenotype was found to be associated with CAT-DI scores, a psychometrically validated severity scale for symptom severity. However, the correlation was weak (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 1003) and varied widely among individuals.

Predictors of symptoms

Depression is one of the world's leading causes of disability1 but is often not properly diagnosed and treated. Depression disorders are usually not treated because of the stigma attached to them, as well as the lack of effective treatments.

To aid in the development of a personalized treatment plan to improve treatment, identifying the predictors of symptoms is important. However, current prediction methods rely on clinical interview, which has poor reliability and only detects a small number of features associated with depression.2

Machine learning can increase the accuracy of diagnosis and treatment for depression by combining continuous, digital behavioral phenotypes gathered from smartphones with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can be used to provide a wide range of unique actions and behaviors that are difficult to document through interviews, and also allow for continuous, high-resolution measurements.

The study involved University of California Los Angeles students with mild to severe depression treatments near me symptoms who were enrolled in the Screening and Treatment for Anxiety and depression treatment centre program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical care in accordance with their severity of depression. Those with a score on the CAT-DI of 35 or 65 were assigned online support via the help of a peer coach. those with a score of 75 were routed to in-person clinical care for psychotherapy.

Participants were asked a set of questions at the beginning of the study concerning their demographics and psychosocial traits. These included sex, age, education, work, and financial status; if they were divorced, married or single; their current suicidal ideas, intent or attempts; and the frequency with which they drank alcohol. The CAT-DI was used for assessing the severity of depression-related symptoms on a scale from zero to 100. The CAT-DI tests were conducted every other week for the participants that received online support, and once a week for those receiving in-person care.

Predictors of Treatment Response

A customized treatment for depression is currently a top research topic and a lot of studies are aimed at identifying predictors that will allow clinicians to identify the most effective drugs for each person. Pharmacogenetics, in particular, identifies genetic variations that determine the way that our bodies process drugs. This lets doctors select the medication that will likely work best for each patient, reducing time and effort spent on trials and errors, while avoiding any side effects.

Another approach that is promising is to build models of prediction using a variety of data sources, combining clinical information and neural imaging data. These models can be used to determine the most effective combination of variables that is predictive of a particular outcome, such as whether or not a drug is likely to improve symptoms and mood. These models can be used to determine the patient's response to a treatment, which will help doctors maximize the effectiveness.

A new generation of machines employs machine learning methods such as algorithms for classification and supervised learning such as regularized logistic regression, and tree-based methods to combine the effects from multiple variables and increase the accuracy of predictions. These models have been proven to be effective in predicting outcomes of treatment for example, the response to antidepressants. These models are getting more popular in psychiatry and it is likely that they will become the norm for future clinical practice.

In addition to prediction models based on ML, research into the underlying mechanisms of depression is continuing. Recent findings suggest that the disorder is linked with neural dysfunctions that affect specific circuits. This suggests that individual depression treatment will be based on targeted therapies that target these circuits in order to restore normal functioning.

One method of doing this is to use internet-based interventions that can provide a more individualized and personalized experience for patients. A study showed that an internet-based program improved symptoms and provided a better quality of life for MDD patients. Furthermore, a randomized controlled study of a personalised approach to depression treatment showed steady improvement and decreased adverse effects in a large number of participants.

Predictors of adverse effects

A major challenge in personalized depression treatment involves identifying and predicting which antidepressant medications will have minimal or no side effects. Many patients are prescribed a variety of medications before settling on a treatment that is safe and effective. Pharmacogenetics provides an exciting new method for an effective and precise approach to selecting antidepressant treatments.

Several predictors may be used to determine which antidepressant to prescribe, including genetic variations, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and co-morbidities. To identify the most reliable and reliable predictors of a specific treatment, randomized controlled trials with larger numbers of participants will be required. This is because the detection of interaction effects or moderators may be much more difficult in trials that only take into account a single episode of treatment per person, rather than multiple episodes of treatment over a period of time.

Furthermore the prediction of a patient's response to a specific medication will likely also need to incorporate information regarding symptoms and comorbidities in addition to the patient's prior subjective experience with tolerability and efficacy. Currently, only a few easily measurable sociodemographic variables as well as clinical variables are reliable in predicting the response to MDD. These include gender, age, race/ethnicity, SES, BMI and the presence of alexithymia.

The application of pharmacogenetics to treatment for depression treatment facility is in its infancy and there are many obstacles to overcome. First is a thorough understanding of the underlying genetic mechanisms is needed and a clear definition of what is a reliable predictor of treatment response. In addition, ethical concerns such as privacy and the appropriate use of personal genetic information, should be considered with care. Pharmacogenetics could, in the long run help reduce stigma around treatments for mental illness and improve the outcomes of treatment. Like any other psychiatric treatment it is crucial to give careful consideration and implement the plan. At present, it's ideal to offer patients a variety of medications for depression that are effective and urge patients to openly talk with their physicians.